Using steroids during cardiopulmonary bypass surgery did not reduce the risk of acute kidney injury in people at increased risk of death, according to a study conducted in 18 countries.
The multi-site randomized controlled trial, funded by the Canadian Institutes of Health Research, included 7,286 patients in Canada, China, India, United States, Colombia, Australia, Italy, Iran, Czech Republic, Greece, Spain, Brazil, Austria, Belgium, Hong Kong, Argentina, Chile and Ireland. Approximately half of the patients (3,647) were randomized to receive steroids during surgery while the remaining half (3,639) did not receive steroids. The rate of acute kidney injury was similar in both groups.
About one-fifth of the millions of bypass surgeries performed around the world each year result in acute kidney injury, which in its most severe forms greatly increases the chance of death and the need for life-sustaining dialysis treatments. Bypass surgery can trigger widespread inflammation, which is thought to be a key culprit in the development of kidney injury. Prior studies suggested that steroids might help reduce inflammation and prevent acute kidney injury.
“Administering steroids to prevent inflammation during surgery did not reduce the risk of acute kidney injury in people at moderate or high risk of adverse effects,” says Dr. Amit Garg, a scientist at Lawson Health Research Institute and professor at Schulich School of Medicine & Dentistry, Western University. “Given the broad range of countries and populations represented in the study, these findings further support a shift away from using steroids as an effective method of preventing the complications from inflammation during bypass surgery.”
The study, “Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial,” is published in CMAJ (Canadian Medical Association Journal).